Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
Primary Purpose
Depression
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ABP688
Sponsored by

About this trial
This is an interventional other trial for Depression focused on measuring ABP688, Tracer, Depression
Eligibility Criteria
Inclusion Criteria:
- Male and female subjects 55-80 (inclusive)
- Subjects in good health
At screening:
- oral body temperature between 35-37.5C
- systolic blood pressure: 90-140 mm Hg
- diastolic blood pressure: 50-90 mm Hg
- pulse rate: 40-90 bpm
- Female subjects of child bearing potential must have been using a double-barrier local contraception
- Postmenopausal women must have had no menstrual bleeding
- Subjects must have weighed at least 50 kg
- All subjects must provide informed consent
- All subjects must have been able to communicate well with investigator
Specific to Major depression disorder (MDD)
Patients had to show following level of symptomatology:
- HAM-D (17-item scale) > 16
- CGI > 4 (moderately ill)
Exclusion Criteria:
Specific criteria for healthy volunteers:
- Presence and/or history of clinically significant major neurological or psychiatric disorder
Specific criteria for MDD patients:
- Presence and/or history of a clinically significant major neurological or psychiatric disorder other than MDD or generalized anxiety disorder
- Axis I co-morbidity was excluded except anxiety spectrum disorders
Criteria for both:
- Smokers
- Pregnancy
- Subjects with history of or symptoms/complaints consistent with mild cognitive impairment
- Use of any psychotropic prescription drugs
- Coffee consumers more than 6 cups/day
- Participation in any clinical investigation
- Donation or loss of 400 mL or more of blood
- Significant illness within 2 weeks prior to dosing
- A known hypersensitivity to study drug
- MRI scan that showed evidence of stroke
- Any surgical or medical condition which might have significantly altered distribution
- Clinical evidence of any abnormal lab value
- History of immunodeficiency disease
- Positive Hepatitis B surface antigen
- Presence of contraindications to PET scan investigations- Presence of contraindications to MRI investigations
- Evidence from an Allen test of incomplete communication
- History of drug or alcohol abuse
- Current use of anticonvulsant
- Significant radiation exposure
Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Novartis Investigative Site
- Novartis Investigative Site
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
ABP688
Arm Description
Elderly MDD patients and demography matched healthy volunteer
Outcomes
Primary Outcome Measures
Binding of [11C] ABP688 to mGlu5 receptors
Binding of [11C]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes
Blood levels of [11C] ABP688
Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of [11C] ABP688. Specific times are recorded at the clinical site.
Secondary Outcome Measures
Difference in [11C]ABP688 binding to mGlu5 receptors
Using data generated as described above, data will be analyzed to determine if there are difference in binding between healthy volunteers and patients.
Full Information
NCT ID
NCT01528241
First Posted
February 3, 2012
Last Updated
December 6, 2020
Sponsor
Novartis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT01528241
Brief Title
Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
Official Title
A Multi-center, Open-label Study in Elderly Healthy Volunteers and Elderly Patients With Major Depressive Disorder to Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
This study is designed to characterize the regional distribution of [11C] ABP688 in brain by positron emission tomography (PET).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
Keywords
ABP688, Tracer, Depression
7. Study Design
Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ABP688
Arm Type
Experimental
Arm Description
Elderly MDD patients and demography matched healthy volunteer
Intervention Type
Drug
Intervention Name(s)
ABP688
Intervention Description
Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
Primary Outcome Measure Information:
Title
Binding of [11C] ABP688 to mGlu5 receptors
Description
Binding of [11C]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes
Time Frame
Day 1
Title
Blood levels of [11C] ABP688
Description
Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of [11C] ABP688. Specific times are recorded at the clinical site.
Time Frame
Day 1, up to 60 minutes
Secondary Outcome Measure Information:
Title
Difference in [11C]ABP688 binding to mGlu5 receptors
Description
Using data generated as described above, data will be analyzed to determine if there are difference in binding between healthy volunteers and patients.
Time Frame
Day 1
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male and female subjects 55-80 (inclusive)
Subjects in good health
At screening:
oral body temperature between 35-37.5C
systolic blood pressure: 90-140 mm Hg
diastolic blood pressure: 50-90 mm Hg
pulse rate: 40-90 bpm
Female subjects of child bearing potential must have been using a double-barrier local contraception
Postmenopausal women must have had no menstrual bleeding
Subjects must have weighed at least 50 kg
All subjects must provide informed consent
All subjects must have been able to communicate well with investigator
Specific to Major depression disorder (MDD)
Patients had to show following level of symptomatology:
HAM-D (17-item scale) > 16
CGI > 4 (moderately ill)
Exclusion Criteria:
Specific criteria for healthy volunteers:
- Presence and/or history of clinically significant major neurological or psychiatric disorder
Specific criteria for MDD patients:
Presence and/or history of a clinically significant major neurological or psychiatric disorder other than MDD or generalized anxiety disorder
Axis I co-morbidity was excluded except anxiety spectrum disorders
Criteria for both:
Smokers
Pregnancy
Subjects with history of or symptoms/complaints consistent with mild cognitive impairment
Use of any psychotropic prescription drugs
Coffee consumers more than 6 cups/day
Participation in any clinical investigation
Donation or loss of 400 mL or more of blood
Significant illness within 2 weeks prior to dosing
A known hypersensitivity to study drug
MRI scan that showed evidence of stroke
Any surgical or medical condition which might have significantly altered distribution
Clinical evidence of any abnormal lab value
History of immunodeficiency disease
Positive Hepatitis B surface antigen
Presence of contraindications to PET scan investigations- Presence of contraindications to MRI investigations
Evidence from an Allen test of incomplete communication
History of drug or alcohol abuse
Current use of anticonvulsant
Significant radiation exposure
Other protocol-defined inclusion/exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
New York
State/Province
New York
Country
United States
Facility Name
Novartis Investigative Site
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
12. IPD Sharing Statement
Links:
URL
https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5125
Description
Results for CABP688A2102 can be found on the Novartis Clinical Trial Results Website
Learn more about this trial
Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
We'll reach out to this number within 24 hrs